$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-009/32
  • A61K-009/36
  • A61K-009/58
  • A61K-009/62
출원번호 US-0003406 (1998-01-06)
우선권정보 IT-0000016 (1997-01-08)
발명자 / 주소
  • Conte Ubaldo,ITX
  • Maggi Lauretta,ITX
  • Grenier Pascal,FRX
  • Vergnault Guy,FRX
  • Zimmer Robert,FRX
출원인 / 주소
  • Jagotec AG, CHX
대리인 / 주소
    Abelman, Frayne & Schwab
인용정보 피인용 횟수 : 76  인용 특허 : 1

초록

Described herein is a particular type of pharmaceutical tablet, for oral use, which is formed by one or more layers, and is specifically designed for controlled release of active principles that present problems of bio-availability linked to absorption in the gastro-intestinal tract, and in particul

대표청구항

[ We claim:] [1.] A pharmaceutical tablet designed for the controlled release of active principles which exhibits a different biological absorption rate in the presence and in the absence of food, which comprises: a core having one or more layers, at least one of which serves as a vehicle for the ac

이 특허에 인용된 특허 (1)

  1. Ohm Andreas (Neuss DEX) Luchtenberg Helmut (Niederkassel DEX) Bcheler Manfred (Overath DEX) Schmoll Josef (Wermelskirchen DEX) Rupp Roland (Leichlingen DEX) Porges Eduard (Cologne DEX) Nishioka Takaa, Dihydropyridine depot formulation.

이 특허를 인용한 특허 (76)

  1. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Amoxicillin-clarithromycin antibiotic composition.
  2. Rudnic, Edward M.; Isbiter, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Amoxicillin-dicloxacillin antibiotic composition.
  3. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Anti-fungal composition.
  4. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Antibiotic composition.
  5. Rudnic, Edward M., Antibiotic composition with inhibitor.
  6. Rudnic,Edward M., Antibiotic composition with inhibitor.
  7. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  8. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  9. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  10. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  11. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  12. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  13. Burnside, Beth A.; Flanner, Henry H.; Rowlings, Colin, Antibiotic product, use and formulation thereof.
  14. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Antibiotic product, use and formulation thereof.
  15. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Antibiotic product, use and formulation thereof.
  16. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Antibiotic product, use and formulation thereof.
  17. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Antiviral product, use and formulation thereof.
  18. Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Antiviral product, use and formulation thereof.
  19. Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Antiviral product, use and formulation thereof.
  20. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Cephalosporin-metronidazole antibiotic composition.
  21. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Ciprofoxacin-metronidazole antibiotic composition.
  22. Storm, Kevin H.; Conley, Creighton P.; Roush, John A., Composition comprising amoxicillin and potassium clavulanate.
  23. Flanner, Henry H.; Guttendorf, Robert J.; Clausen, Susan P.; Treacy, Donald; Burnside, Beth A., Compositions and methods for improved efficacy of penicillin-type antibiotics.
  24. Odidi, Isa, Compositions and methods for reducing overdose.
  25. Odidi, Isa, Compositions and methods for reducing overdose.
  26. Odidi, Isa, Compositions and methods for reducing overdose.
  27. Odidi, Isa, Compositions and methods for reducing overdose.
  28. Storm,Kevin H.; Conley,Creighton P.; Roush,John A., Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan.
  29. Grenier, Pascal; Nhamias, Alain; Vergnault, Guy, Controlled release compositions.
  30. Grenier, Pascal; Nhamias, Alain; Vergnault, Guy, Controlled release nisoldipine compositions.
  31. Patrick S. -L. Wong ; Liang C. Dong ; Jiansheng Wan, Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
  32. Wong, Patrick S. L.; Dong, Liang C.; Wan, Jiansheng, Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
  33. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Erythromyacin antibiotic product, use and formulation thereof.
  34. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Fluroquinilone antibiotic product, use and formulation thereof.
  35. Neely, Jason; Wargo, David J.; Li, Boyong; Reynolds, Thomas D., Formulation and method for the release of paroxetine in the large intestine.
  36. Berner, Bret; Louie-Helm, Jenny; Shell, John W., Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract.
  37. Berner, Bret; Louie-Helm, Jenny; Shell, John W., Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract.
  38. Vergnault, Guy; Grenier, Pascal; Maggi, Lauretta; Conte, Ubaldo, Hydrophilic/lipophilic polymeric matrix dosage formulation.
  39. Vergnault, Guy; Grenier, Pascal; Maggi, Lauretta; Conte, Ubaldo, Hydrophilic/lipophilic polymeric matrix dosage formulation.
  40. Gumaste, Anand; Akouka, Henri, Inhalation device.
  41. Gumaste, Anand; Akouka, Henri, Inhalation device.
  42. Gumaste, Anand; Akouka, Henri, Inhalation device.
  43. Akouka, Henri M.; Becker, Daniel P., Inhalation device and method.
  44. Akouka, Henri M.; Becker, Daniel P., Inhalation device and method.
  45. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Levofloxacin antibiotic product, use and formulation thereof.
  46. Abrams, Andrew L.; Gumaste, Anand V., Metering and packaging of controlled release medication.
  47. Abrams,Andrew L.; Gumaste,Anand V., Metering and packaging of controlled release medication.
  48. Andrew L. Abrams ; Anand V. Gumaste, Metering and packaging of controlled release medication.
  49. Ueki, Yosuke; Suzuki, Yasuyuki; Fujioka, Satoshi, Method for stabilizing anti-dementia drug.
  50. Ueki, Yosuke; Suzuki, Yasuyuki; Fujioka, Satoshi, Method for stabilizing anti-dementia drug.
  51. Storm,Kevin H.; Conley,Creighton P.; Roush,John A., Method of treating a bacterial infection.
  52. Conley, Creighton P.; Roush, John A.; Storm, Kevin H., Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate.
  53. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Metronidazole antibiotic product, use and formulation thereof.
  54. Flanner, Henry H.; Tolle-Sander, Sanna; Treacy, Donald; Burnside, Beth A.; Clausen, Susan P., Modified release amoxicillin products.
  55. Conley, Creighton P.; Roush, John A.; Storm, Kevin H., Modified release pharmaceutical formulation comprising amoxycillin.
  56. Hsu, Ann; Dong, Liang C.; Ding, Amy; Gupta, Suneel, Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof.
  57. Rademacher, Tina; Seibertz, Frank; Brandt, Petra; Krumme, Markus; Von Falkenhausen, Christian, Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine.
  58. Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Multiple-delayed release anti-neoplastic product, use and formulation thereof.
  59. Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Multiple-delayed release anti-viral product, use and formulation thereof.
  60. Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Multiple-delayed release antifungal product, use and formulation thereof.
  61. Rudnic,Edward M.; Isbister,James D.; Treacy, Jr.,Donald J.; Wassink,Sandra E., Multiple-delayed released antibiotic product, use and formulation thereof.
  62. Rudnic, Edward M; Isbister, James D; Treacy, Jr., Donald J; Wassink, Sandra E, Once a day amoxicillin product comprising immediate and delayed release dosage forms.
  63. Flanner, Henry H.; Guttendorf, Robert; Treacy, Donald; Clausen, Susan P.; Burnside, Beth A., Pharmaceutical compositions and methods for improved bacterial eradication.
  64. Christian Desesquelle FR; Philippe Becourt FR, Pill tablet.
  65. Cao, Bruce X.; Burnside, Beth A.; Wassink, Sandra E.; Baker, Matt R., Robust pellet.
  66. Grimmett, Francis Walter; Davidson, Nigel Philip McCreath, Tablet containing a coated core.
  67. Cao, Bruce; Wassink, Sandra E.; Treacy, Jr., Donald J.; Burnside, Beth A.; Rowlings, Colin E.; Bonck, John A., Tablet for pulsed delivery.
  68. Caroline Sassano Slone ; Kevin Rodney Lassila, Tartaric acid diesters as biodegradable surfactants.
  69. Slone, Caroline Sassano; Lassila, Kevin Rodney, Tartaric acid diesters as biodegradable surfactants.
  70. Slone, Caroline Sassano; Lassila, Kevin Rodney, Tartaric acid diesters as biodegradable surfactants.
  71. Appel, Leah Elizabeth; Friesen, Dwayne Thomas; LaChapelle, Edward Dennis; Konagurthu, Sanjay; Falk, Richard Frank; Reo, Joseph P., Taste-masked drugs in rupturing multiparticulates.
  72. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Tetracycline antibiotic product, use and formulation thereof.
  73. Rudnic, Edward M.; Isbister, James D.; Treacy, Jr., Donald J.; Wassink, Sandra E., Tetracycline--doxycycline antibiotic composition.
  74. Gale, Robert M., Transparent transdermal nicotine delivery devices.
  75. Gale, Robert M., Transparent transdermal nicotine delivery devices.
  76. Gale, Robert M., Transparent transdermal nicotine delivery devices.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로